Sobre mi

Cap del Servei de Pneumologia i Al•lèrgia Respiratòria de l'Hospital Clínic de Barcelona. Actualment, Cap de la Unitat d'Hipertensió Pulmonar de l'Hospital Clínic, Unitat Nacional de Referència d'Hipertensió Pulmonar Complexa, pertanyent a la Xarxa Europea de Referència de Malalties Pulmonars Rares (ERN-LUNG). Els seus interessos de recerca se centren en la patogènesi de la hipertensió pulmonar associada a la malaltia pulmonar obstructiva crònica, tant a nivell cel•lular com molecular, i en la fisiologia de la regulació vascular de l'intercanvi de gasos.

Publicacions destacades

  • ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension

    Autors: Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jurevi?ien? E, Kiely DG, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock AJ .
    Referència: EUROPEAN RESPIRATORY JOURNAL 2019; 53(2):-.
  • The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension

    Autors: Newnham M; South K; Bleda M; Auger WR; Barberà JA; Bogaard H; Bunclark K; Cannon JE; Delcroix M; Hadinnapola C; Howard LS; Jenkins D; Mayer E; Ng C; Rhodes CJ; Screaton N; Sheares K; Simpson MA; Southwood M; Su L; Taboada D; Traylor M; Trembath RC; Villar SS; Wilkins MR; Wharton J; Gräf S; Pepke-Zaba J; Laffan M; Lane DA; Morrell NW; Toshner M .
    Referència: EUROPEAN RESPIRATORY JOURNAL 2019.
  • Pulmonary Vascular Density: Comparison of Findings on CT Imaging with Histology

    Autors: Rahaghi FN, Argemí G, Nardelli P, Domínguez-Fandos D, Arguis P, Peinado VI, Ross JC, Ash SY, de La Bruere I, Come CE, Diaz AA, Sánchez M, Washko GR, Barberà JA, San José Estépar R .
    Referència: EUROPEAN RESPIRATORY JOURNAL 2019.
  • Pulmonary hypertension in chronic lung disease and hypoxia

    Autors: Nathan SD; Barbera JA; Gaine SP; Harari S; Martinez FJ; Olschewski H; Olsson KM; Peacock AJ; Pepke-Zaba J; Provencher S; Weissmann N; Seeger W.
    Referència: 2019.
  • Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy.

    Autors: Huertas A; Guignabert C; Barberà JA; Bärtsch P; Bhattacharya J; Bhattacharya S; Bonsignore MR; Dewachter L; Dinh-Xuan AT; Dorfmüller P; Gladwin MT; Humbert M; Kotsimbos T; Vassilakopoulos T; Sanchez O; Savale L; Testa U; Wilkins MR.
    Referència: EUROPEAN RESPIRATORY JOURNAL 2018.
  • Pulmonary Vascular Involvement in COPD - Is There a Pulmonary Vascular Phenotype?

    Autors: Kovacs G, Agusti A, Barberà JA, Celli B, Criner G, Humbert M, Sin DD, Voelkel N, Olschewski H .
    Referència: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2018.
  • Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): Subgroup analysis from the AMBITION trial

    Autors: Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ.
    Referència: ANNALS OF THE RHEUMATIC DISEASES 2017.
  • An official European Respiratory Society statement: pulmonary haemodynamics during exercise.

    Autors: Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grünig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, Olschewski H .
    Referència: EUROPEAN RESPIRATORY JOURNAL 2017.
  • Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study

    Autors: Hoeper; Marius M McLaughlin; Vallerie V Albert Barbera; Joan Frost; Adaani E Ghofrani; Hossein-Ardeschir Peacock; Andrew J Simonneau; Gerald Rosenkranz; Stephan Oudiz; Ronald J White; R James Miller; Karen L Langley; Jonathan Harris; Julia H N Blair; Christiana Rubin; Lewis J Vachiery; Jean-Luc.
    Referència: THE LANCET. RESPIRATORY MEDICINE 2016.
  • Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry

    Autors: Delcroix M; Lang I; Pepke-Zaba J; Jansa P; D'Armini AM; Snijder R; Bresser P; Torbicki A; Mellemkjaer S; Lewczuk J; Simkova I; Barberà JA; de Perrot M; Hoeper MM; Gaine S; Speich R; Gomez-Sanchez MA; Kovacs G; Jaïs X; Ambroz D; Treacy C; Morsolini M; Jenkins D; Lindner J; Dartevelle P; Mayer E; Simonneau G .
    Referència: CIRCULATION 2016.

Projectes destacats

  • Caracterización fenotípica de la hipertensión pulmonar en las enfermedades respiratorias

    Finançador: INSTITUTO DE SALUD CARLOS III
    Durada: 01/01/2019 - 31/12/2021
  • Proliferación celular en la hipertensión pulmonar: Detección y mecanismos de regulación epigenética

    Finançador: INSTITUTO DE SALUD CARLOS III
    Durada: 01/01/2016 - 31/12/2018
  • Recerca traslacional en malalties pulmonars

    Investigador/a principal: Joan Albert Barberà
    Finançador: AGÈNCIA DE GESTIÓ D’AJUTS UNIVERSITARIS I DE RECERCA
    Durada: 01/03/2018 - 28/02/2021
  • Targeting endothelial dysfunction in highly prevalent diseases: characterization and validation of prognostic biomarkers and identification of potential therapeutic strategies

    Investigador/a principal: Joan Albert Barberà
    Finançador: INSTITUTO DE SALUD CARLOS III
    Durada: 01/01/2016 - 31/12/2018
  • MoGlyNet. Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study

    Investigador/a principal: Joan Albert Barberà
    Finançador: UNIÓN EUROPEA
    Durada: 15/09/2015 - 31/12/2019